Description

Product Availability: In Stock (delivery within 2-3 business days, no extra charge for drop-shipping).

Ordering: To place an order via credit card or PO use Add to Cart button (creating an account is not required).

Transfection Reagent for Neuro-2a Cells (Neuroblastoma Cells, CCL-131)

• Proprietary cationic lipids formulation
• Effective and robust intracellular delivery
• Kit includes Transfection Enhancer reagent
• Produces consistent results, lot-to-lot, plate-to-plate, and well-to-well
• Work in the presence of serum
• A proven reagent for establishing stable cell lines
• Download in vitro Neuro2a transfection protocol: [PDF]
• Download Neuro2a CRISPR/Cas9 transfection protocol: [PDF]
• Download PowerPoint presentation for Neuro2a cells transfection kit: [PPT]
• Developed and manufactured by Altogen Biosystems

Transfection Efficiency:

Reagent exhibits at least 71% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.

Transfection Protocol and MSDS:

Download Altogen Biosystems Neuro2a Transfection Protocol: [PDF]

Download MSDS: [PDF]

Neuro-2a Cell Line:

Neuroblastoma is the most frequent extracranial solid tumor in children, and roughly half of the patients experience bone metastasis accompanied by bone pain, leading to poor prognosis for those affected. The Neuro-2a cell line was established from brain tissue of an albino house mouse (Mus musculus) with neuroblastoma. These cells exhibit neuronal and amoeboid stem cell morphology, making them uniquely useful for scientific study. Also, the Neuro-2a cell line is susceptible to herpes simplex virus, human poliovirus 1, and vesicular stomatitis virus. Neuro-2a cells have been known to create large amounts of microtubular protein. Neuro-2a cells make for reliable transfection hosts due to their neuronal and amoeboid morphology. Altogen Biosystems offers in vitro transfection reagents delivering satisfactory results, including a liposome formulation Neuro-2a transfection reagent kit for neuroblastoma cells that yields high transfection efficiency and is considered an appropriate host for studying brain tumors.

Data:

Figure 1. Cyclophilin B silencing efficiency was determined by qRT-PCR in Neuro2a cells transfected by Cyclophilin B siRNA or non-silencing siRNA control following the recommended transfection protocol. Cyclophilin mRNA expression levels were measured 48 hours post-transfection. 18S rRNA levels were used to normalize the Cyclophilin B data. Values are normalized to untreated sample. Data are presented as means ± SD (n=6).

Figure 2. Protein expression of Cyclophilin B in Neuro-2a cells. DNA plasmid expressing Cyclophilin B or siRNA targeting Cyclophilin B were transfected into Neuro-2a cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.

Altogen Biosystems:
Altogen Biosystems is a life sciences company that manufactures over 100 cell type specific and pre-optimized transfection kits, electroporation buffers, and targeted in vivo delivery kits and reagents. Advanced formulation of reagents and optimized transfection protocols provide highly efficient intracellular delivery of biomolecules (proteins, DNA, mRNA, shRNA and siRNA, and small molecule compounds). Read more about transfection technology at Altogen’s Transfection Resource.

Altogen Labs Research Services:

Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).

Volume Options:

• 0.5 ml (Catalog #6872)
• 1.5 ml (Catalog #6873)
• 1.5 ml CRISPR (Catalog #2184)
• 8.0 ml (Catalog #7073)